NeuroSigma prepares for Phase III trial of Monarch eTNS system

07/29/2013 | (Boston)

NeuroSigma has secured FDA approval to start a Phase III clinical trial investigating the Monarch eTNS system for treatment of epilepsy. The device transmits an electrical pulse to the patient through a soft patch attached to the forehead. PET imaging confirmed the treatment targets epilepsy-affected regions. The company plans to conduct multicenter trials in the U.S., Europe and Canada.

View Full Article in: (Boston)

Published in Brief:

SmartBrief Job Listings for Health Care

Job Title Company Location
Health Care Exchange Account Manager
Kaiser Permanente
San Diego, CA
Director, Health Plan Claims Operations
Group Health Cooperative
Seattle, WA
Stop Loss Sales Executive
Blue Cross Blue Shield of MA
Boston, MA
Field Representative-Oklahoma and Kansas
National Rural Electric Cooperative Association (NRECA)
Multiple Locations, SL_Multiple Locations
Vice President, Idaho Regional Director
Boise, ID